Skip to main content
Evidence Snapshot

Enterococcus faecium

CHEMBL357 ORGANISM Enterococcus faecium
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL357
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Enterococcus faecium as ChEMBL target CHEMBL357. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Enterococcus faecium
ORGANISM · Enterococcus faecium
As of 2026-09-13
ChEMBL target ID
CHEMBL357
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Enterococcus faecium matters

As of 2026-09-13

Enterococcus faecium is reviewed as Enterococcus faecium; the current evidence base includes 13 approved drugs, 7852 compounds, and 1925 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 7852 compounds, and 1925 assays for this target. The dominant activity type is IC50. CHEMBL4289275 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4289275 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Enterococcus faecium matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

7852
Total Compounds
1925
Total Assays
13
Approved Drugs
IC50: 275.0, EC50: 96.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4289275
 10.3 EC50 —
No preferred name
CHEMBL129788
 10.0 IC50 —
No preferred name
CHEMBL1160200
 9.9 IC50 —
No preferred name
CHEMBL422395
 9.9 IC50 —
No preferred name
CHEMBL34259
 9.5 IC50 Approved

Approved Drugs

Structure Compound First Approval
TRIMETHOPRIM
CHEMBL22
 1973
RIFAMPIN
CHEMBL374478
 1971
AMPICILLIN
CHEMBL174
 1965
VANCOMYCIN
CHEMBL262777
 1964
METHOTREXATE
CHEMBL34259
 1953
PYRIMETHAMINE
CHEMBL36
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL357